Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: Results of European intergroup randomized trial comparing autografting versus observation

Blood

Volumn 117, Issue 5, 2011, Pages 1516-1521

  Michallet, Mauricette ^a   Dreger, Peter ^b   Sutton, Laurent ^c   Brand, Ronald ^d   Richards, Sue ^e   Van Os, Marleen ^d   Sobh, Mohamad ^a   Choquet, Sylvain ^f   Corront, Bernadette ^g   Dearden, Claire ^h   Gratwohl, Alois ⁱ   Herr, Wolfgang ^j   Catovsky, Daniel ^k   Hallek, Michael ^l   De Witte, Theo ^m   Niederwieser, Dietger ⁿ   Leporrier, Michel ^o   Milligan, Donald ^p  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^d EBMT Department of Medical Statistics   (Netherlands)

^e CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g Centre Hospitalier de la Region d'Annecy   (France)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^l UNIVERSITY OF COLOGNE   (Germany)

^m RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

ⁿ UNIVERSITY OF LEIPZIG   (Germany)

^o CAEN UNIVERSITY HOSPITAL   (France)

^p BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; MESNA; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFIDENCE INTERVAL; EVENT FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

EID: 79551631475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-308775     Document Type: Article

References (32)

1. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94(2):448-454.
2. Yee KW, O'Brien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(8):1105-1129.
3. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370(9583):230-239.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
5. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19(6):1029-1033.
6. Ritgen M, Bottcher S, Stilgenbauer S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008;22(7):1377-1386.
7. Delgado J, Milligan DW, Dreger P. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood. 2009;114(13):2581-2588.
8. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001;15(3):445-451.
9. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994;12(4):748-758.
10. Pavletic ZS, Bierman PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998;9(9):1023-1026.
11. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer. 1998;77(12):2291-2297.
12. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389-4396.
13. Dreger P, Döhner H, Greinix H, McClanahan F. Early autologous stem cell transplantation (auto-SCT) may overcome the adverse impact of Del 11q- in poor-risk chronic lymphocytic leukemia (CLL): results from the GCLLSG CLL3 trial [abstract]. Blood. 2009;114. Abstract 879.
14. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105(1):397-404.
15. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103(7):2850-2858.
16. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88(6):2228-2235.
17. Jantunen E, Itala M, Siitonen T, et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant. 2006;37(12):1093-1098.
18. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004;103(1):363-365.
19. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol. 1999;105(3):775-779.
20. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood. 2006;107(4):1276-1283.
21. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101(5):2049-2053.
22. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23(15):3433-3438.
23. Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovsky D. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol. 2006;133(2):173-175.
24. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
25. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206.
26. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer. 1978;37(5):849-857.
27. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
29. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99(6):2245-2247.
30. Dreger P, Brand R, Michallet M. Autologous stem cell transplantation for chronic lymphocytic leukemia. Semin Hematol. 2007;44(4):246-251.
31. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24(15):2337-2342.
32. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia. 2002;16(6):985-992.